Skip to main content
SpringerLink
Log in

Effector Immune Cell Deployment: a revolutionized concept in cancer immunotherapy

  • Insight
  • Published:
Science China Life Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Chen, X., and Song, E. (2022). The theory of tumor ecosystem. Cancer Commun 42, 587–608.

    Article  Google Scholar 

  • Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A.P., Zhu, Z., Zhang, J., Benson, D.M., He, K., Caligiuri, M.A., et al. (2019). The mechanism of Anti—PD-Ll antibody efficacy against PD-Ll—Negative tumors identifies NK Cells expressing PD-L1 as a cytolytic effector. Cancer Discovery 9, 1422–1437.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guo, X., and Dong, C. (2022). Zooming on T cells in cancer. Sci China Life Sci 65, 1466–1468.

    Article  PubMed  Google Scholar 

  • Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018). Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24, 1550–1558.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim, R., Emi, M., and Tanabe, K. (2007). Cancer immunoediting from immune surveillance to immune escape. Immunology 121, 1–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mlecnik, B., Bifulco, C., Bindea, G., Marliot, F., Lugli, A., Lee, J.J., Zlobec, I., Rau, T.T., Berger, M.D., Nagtegaal, I.D., et al. (2020). Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol 38, 3638–3651.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Seya, T., Begum, N.A., Nomura, M., Tsuji, S., Matsumoto, M., Hayashi, A., Azuma, I., and Toyoshima, K. (2000). Innate immune therapy for cancer. Screen for molecules capable of activating the innate immune system. Adv Exp Med Biol 465, 229–237.

    Article  CAS  PubMed  Google Scholar 

  • Zhang, J., Huang, D., Saw, P.E., and Song, E. (2022). Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol 43, 523–545.

    Article  CAS  PubMed  Google Scholar 

  • Zhang, Y., and Zhang, Z. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17, 807–821.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhao, Z., Xiao, X., Saw, P.E., Wu, W., Huang, H., Chen, J., and Nie, Y. (2020). Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment. Sci China Life Sci 63, 180–205.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Key Research and Development Program of China (2021YFA1300502), the Natural Science Foundation of China (92057210, 82125017, 91942309).

Author information

Authors and Affiliations

  1. Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China

    Shicheng Su

  2. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China

    Shicheng Su

  3. Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China

    Shicheng Su

  4. Biotherapy Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China

    Shicheng Su

Authors
  1. Shicheng Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shicheng Su.

Ethics declarations

Compliance and ethics All author(s) declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Su, S. Effector Immune Cell Deployment: a revolutionized concept in cancer immunotherapy. Sci. China Life Sci. 66, 1930–1933 (2023). https://doi.org/10.1007/s11427-022-2184-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11427-022-2184-6

Search

Navigation